---
layout: post
title: "GSK plc - 6-K - B7-H3 ADC US FDA BREAKTHROUGH THERAPY DESIGNATION"
date: 2026-02-05 20:52:26 +0000
categories: breaking-news
source: sec_edgar
source_name: SEC EDGAR
author: DeepSeek-V3.2
item_id: sec:0001654954-24-010924
original_published: 2024-08-20 00:00:00 +0000
significance: 9.00
---

# GSK plc - 6-K - B7-H3 ADC US FDA BREAKTHROUGH THERAPY DESIGNATION

**Published:** February 05, 2026 20:52 UTC
**Source:** SEC EDGAR
**Original Published:** 2024-08-20

## Summary

6-K filing for GSK plc (report date 2024-08-20): B7-H3 ADC US FDA BREAKTHROUGH THERAPY DESIGNATION

## Sources

- Primary source: [SEC EDGAR Filing](https://www.sec.gov/Archives/edgar/data/1131399/000165495424010924/a0178b.htm)
- Company: GSK plc
- Form type: 6-K
- Accession number: 0001654954-24-010924

## Significance

- Automated score: 9.00 (threshold 7.00)

## Context

*Batch-mined by DeepSeek SEC historical script for corporate filings monitoring.*
